Intas Pharma on the Prowl for Larger Stake in Teva’s European Ops

Published: Aug 11, 2017

MUMBAI: Within a year of buying out Teva's UK and Ireland assets and breaking into the top 20 generics players club, Intas Pharmaceuticals is on the prowl again for a larger piece of Teva’s existing operations in Europe.

The closely held Ahmedabad-based drug maker, which has Temasek and Chrys Capital as its investors, is bidding for Teva’s women's health, oncology and pain management divisions in Europe for $1.5 billion, said multiple sources aware of the ongoing negotiations.

Back to news